Order Article Reprints

Aftimos P, Rolfo C, Rottey S, Barthélémy P, Borg C, Park K, Oh D-Y, Kim S-W, De Jonge N, Hanssens V, et al. The NHance^® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. Biomedicines. 2021; 9(6):665. https://doi.org/10.3390/biomedicines9060665

Aftimos, Philippe, Christian Rolfo, Sylvie Rottey, Philippe Barthélémy, Christophe Borg, Keunchil Park, Do-Youn Oh, Sang-We Kim, Natalie De Jonge, Valérie Hanssens, and et al. 2021. "The NHance^® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients" Biomedicines 9, no. 6: 665. https://doi.org/10.3390/biomedicines9060665

Aftimos, P., Rolfo, C., Rottey, S., Barthélémy, P., Borg, C., Park, K., Oh, D.-Y., Kim, S.-W., De Jonge, N., Hanssens, V., Zwanenpoel, K., Molthoff, C., Vugts, D., Dreier, T., Verheesen, P., van Dongen, G. A. M. S., Jacobs, J., Van Rompaey, L., Hultberg, A., ... Awada, A. (2021). The NHance^® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. Biomedicines, 9(6), 665. https://doi.org/10.3390/biomedicines9060665